Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
KalVista Pharmaceuticals ( (KALV) ) has shared an update.
On July 7, 2025, KalVista Pharmaceuticals announced the FDA approval of EKTERLY® (sebetralstat), a novel plasma kallikrein inhibitor, as the first and only oral on-demand treatment for hereditary angioedema (HAE) in patients aged 12 and older. This approval, based on the phase 3 KONFIDENT clinical trial, marks a significant advancement in HAE treatment, offering rapid symptom relief and a favorable safety profile. The approval is expected to transform the management of HAE, providing patients with greater independence and control over their condition.
The most recent analyst rating on (KALV) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on KalVista Pharmaceuticals stock, see the KALV Stock Forecast page.
Spark’s Take on KALV Stock
According to Spark, TipRanks’ AI Analyst, KALV is a Neutral.
KalVista Pharmaceuticals exhibits substantial financial challenges with weak revenue generation and profitability. While technical indicators show mixed momentum, the company’s strategic agreement with Kaken Pharmaceutical provides a potential growth avenue. However, the negative P/E ratio and lack of dividend yield negatively impact valuation. Overall, the stock’s score reflects financial struggles counterbalanced by strategic opportunities.
To see Spark’s full report on KALV stock, click here.
More about KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and delivering oral therapies for rare diseases with significant unmet needs. In the U.S., the company markets EKTERLY®, the first and only oral on-demand treatment for hereditary angioedema (HAE), and has multiple regulatory applications under review in key global markets.
Average Trading Volume: 740,591
Technical Sentiment Signal: Hold
Current Market Cap: $595.6M
For detailed information about KALV stock, go to TipRanks’ Stock Analysis page.